A New Paradigm for Noninvasive Treatment of Metabolic Diseases
Completely Novel and Category-creating Platform
Unlike conventional weight-loss treatments including "Restrictive Devices," "Malabsorption Devices," "Bariatric Surgeries," and "Weight-loss drugs," which generally work against nature, EndoSphere's endoscopic device works with the body's natural physiological responses to food ingestion to help amplify satiety and restore the normal regulatory functions of the Duodenum.
Our emphasis is uniquely placed on the Duodenum, the body's Metabolic Control Center, because this upper-intestinal organ is involved with so many important functions including Satiety Regulation, Insulin Management, Digestion, and Drug Delivery. Even though the Duodenum is widely recognized by the scientific community for its natural role as a Metabolic Control Center, most conventional weight-loss treatments focus instead on restricting the Stomach's available capacity, or interrupting the intestinal tract's natural absorption functions.
EndoSphere is the industry's first pioneer to focus deliberately on the importance of treating the Duodenum as the body's Metabolic Control Center. Our "Endo-Metabolic"devices are designed to enable incisionless, reversible and repeatable therapies, and represent a new paradigm for enabling improved outcomes for patients suffering from obesity and other metabolic diseases.
News & Industry Recognitions
Obesity, the Next Big Thing in Medical Devices
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
EndoSphere receives top industry recognition, named to "Fierce 15" list of the world's most promising privately-held medical technology innovators
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
EndoSphere's next-generation endoscopic device receives CE Mark regulatory approval
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
EndoSphere receives Innovation Award of $1 million to advance platform of next-generation endoscopic medical devices
Columbus, OH - April 19, 2012. EndoSphere today announced that the Ohio Department of Development's Innovation Fund has awarded $1 million to support EndoSphere’s platform of non-invasive, endoscopically-implantable devices that treat metabolic diseases including obesity and type 2 diabetes.
EndoSphere receives pivotal patent approval by USPTO; Wins broad coverage of claims relating to its breakthrough endoscopic technology for treating obesity
Columbus, Ohio - June 15, 2011. EndoSphere Inc., a medical technology company that holds 23 U.S. and international issued and pending patents, announced today that the U.S. Patent and Trademark Office has issued the company a patent covering the use of its endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes.
Broadline Capital leads EndoSphere's Series A preferred financing round
Columbus, Ohio - June 1, 2011. EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of an oversubscribed Series A Preferred Financing round led by Broadline Capital, a global private equity investment firm. EndoSphere holds numerous U.S. and international issued and pending patents, and plans to use the funding to expand its intellectual property assets and to complete additional clinical product testing.